Sulfonylharnstoffderivate und Ihre Verwendung zur Behandlung von Krebs
EP4741375
13. Mai 2026
Anmelder: Qubit Pharmaceuticals 🇫🇷
Details
- Veröffentlichungs-Nr.
- EP4741375
- Anmeldetag
- 6. November 2024
- Veröffentlichung
- 13. Mai 2026
- Rechtsraum
- EP
- IPC
- (DIETRICH HENRI et al.)(GLEASON JOHN G et al.)(SCHENKER ERHARD et al.)(WELLINGA KOBUS et al.)(BROAD INST INC et al.)(BAYER AG et al.)
Abstract
The present disclosure describes sulfonylurea derivatives compounds of Formula (I), and pharmaceutically acceptable salts thereof, compositions, methods, and uses thereof. Such compounds are believed to be therapeutically useful as inhibitors of KAT6A with improved selectivity particularly in the treatment and/or prevention of diseases and disorders mediated by KAT6A in a subject.
Anmelder
- Firma
- Qubit Pharmaceuticals
- Land
- 🇫🇷 Frankreich
Vertreten von
-
A.P.I. Conseil
A.P.I. Conseil · Pau